S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
S&P 500   3,669.01 (+0.18%)
DOW   29,883.79 (+0.20%)
QQQ   303.85 (+0.13%)
AAPL   123.08 (+0.29%)
MSFT   215.37 (-0.39%)
FB   287.52 (+0.34%)
GOOGL   1,824.97 (+1.65%)
AMZN   3,203.53 (-0.51%)
TSLA   568.82 (-2.73%)
NVDA   541.78 (+1.15%)
BABA   261.32 (-1.02%)
CGC   28.18 (+5.74%)
GE   10.43 (+2.76%)
MU   69.11 (+3.03%)
AMD   93.74 (+1.20%)
T   29.09 (+0.76%)
NIO   47.98 (+5.78%)
F   9.20 (-0.43%)
ACB   10.95 (+12.31%)
NFLX   503.38 (-0.24%)
BA   223.85 (+5.09%)
GILD   61.13 (+0.02%)
DIS   153.61 (+2.79%)
Log in
NASDAQ:CARA

Cara Therapeutics Stock Forecast, Price & News

$14.90
+0.21 (+1.43 %)
(As of 12/2/2020 04:42 PM ET)
Add
Compare
Today's Range
$14.53
Now: $14.90
$15.06
50-Day Range
$12.72
MA: $14.43
$16.16
52-Week Range
$8.88
Now: $14.90
$20.70
Volume412,366 shs
Average Volume480,094 shs
Market Capitalization$742.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76
Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.
Cara Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.63 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CARA
CUSIPN/A
Phone203-406-3700
Employees72

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$19.89 million
Book Value$2.57 per share

Profitability

Net Income$-106,370,000.00
Net Margins-360.35%

Miscellaneous

Market Cap$742.50 million
Next Earnings Date2/25/2021 (Estimated)
OptionableOptionable
$14.90
+0.21 (+1.43 %)
(As of 12/2/2020 04:42 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CARA News and Ratings via Email

Sign-up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cara Therapeutics (NASDAQ:CARA) Frequently Asked Questions

How has Cara Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Cara Therapeutics' stock was trading at $13.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CARA stock has increased by 10.4% and is now trading at $14.83.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cara Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cara Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cara Therapeutics
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Cara Therapeutics?

Wall Street analysts have given Cara Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Cara Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Cara Therapeutics' next earnings date?

Cara Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Cara Therapeutics
.

How were Cara Therapeutics' earnings last quarter?

Cara Therapeutics, Inc. (NASDAQ:CARA) announced its quarterly earnings results on Saturday, November, 14th. The biopharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.60) by $0.25. Cara Therapeutics had a negative return on equity of 64.36% and a negative net margin of 360.35%.
View Cara Therapeutics' earnings history
.

What price target have analysts set for CARA?

4 analysts have issued twelve-month price objectives for Cara Therapeutics' stock. Their forecasts range from $30.00 to $40.00. On average, they expect Cara Therapeutics' share price to reach $34.50 in the next twelve months. This suggests a possible upside of 132.6% from the stock's current price.
View analysts' price targets for Cara Therapeutics
.

Are investors shorting Cara Therapeutics?

Cara Therapeutics saw a drop in short interest in the month of October. As of October 30th, there was short interest totaling 3,830,000 shares, a drop of 15.3% from the October 15th total of 4,520,000 shares. Based on an average trading volume of 390,200 shares, the days-to-cover ratio is currently 9.8 days. Approximately 10.7% of the company's shares are short sold.
View Cara Therapeutics' Short Interest
.

Who are some of Cara Therapeutics' key competitors?

What other stocks do shareholders of Cara Therapeutics own?

Who are Cara Therapeutics' key executives?

Cara Therapeutics' management team includes the following people:
  • Dr. Derek T. Chalmers, Co-Founder, Pres, CEO & Director (Age 56, Pay $881.83k)
  • Dr. Frédérique Menzaghi, Chief Scientific Officer and Sr. VP of R&D (Age 54, Pay $597.83k)
  • Mr. Scott M. Terrillion, Chief Compliance Officer, Gen. Counsel & Corp. Sec. (Age 57, Pay $571.03k)
  • Dr. Michael E. Lewis, Co-Founder & Chief Scientific Advisor (Age 68)
  • Mr. Thomas Charles Reilly, Chief Financial Officer
  • Mr. Richard Makara, VP, Head of Accounting, Controller & Principal Accounting Officer (Age 49)
  • Mr. Eric Vandal, Sr. VP of Commercial
  • Dr. Joana Goncalves, Chief Medical Officer (Age 46)

What is Cara Therapeutics' stock symbol?

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Who are Cara Therapeutics' major shareholders?

Cara Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.88%), State Street Corp (2.03%), Pinnacle Associates Ltd. (0.86%), Charles Schwab Investment Management Inc. (0.56%), Assenagon Asset Management S.A. (0.35%) and LPL Financial LLC (0.32%). Company insiders that own Cara Therapeutics stock include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Mani Mohindru, Martin Vogelbaum and Scott Terrillion.
View institutional ownership trends for Cara Therapeutics
.

Which major investors are selling Cara Therapeutics stock?

CARA stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Aigen Investment Management LP, Victory Capital Management Inc., Pinnacle Associates Ltd., Wells Fargo & Company MN, JPMorgan Chase & Co., and WINTON GROUP Ltd. Company insiders that have sold Cara Therapeutics company stock in the last year include Christopher Posner, Derek T Chalmers, Frederique PhD Menzaghi, Jeffrey L Ives, Joana Goncalves, Mani Mohindru, Martin Vogelbaum, and Scott Terrillion.
View insider buying and selling activity for Cara Therapeutics
.

Which major investors are buying Cara Therapeutics stock?

CARA stock was purchased by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., State of New Jersey Common Pension Fund D, Arrowstreet Capital Limited Partnership, Squarepoint Ops LLC, UBS Asset Management Americas Inc., Cubist Systematic Strategies LLC, AlphaCrest Capital Management LLC, and Alpine Woods Capital Investors LLC.
View insider buying and selling activity for Cara Therapeutics
.

How do I buy shares of Cara Therapeutics?

Shares of CARA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cara Therapeutics' stock price today?

One share of CARA stock can currently be purchased for approximately $14.83.

How big of a company is Cara Therapeutics?

Cara Therapeutics has a market capitalization of $739.01 million and generates $19.89 million in revenue each year. The biopharmaceutical company earns $-106,370,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Cara Therapeutics employs 72 workers across the globe.

What is Cara Therapeutics' official website?

The official website for Cara Therapeutics is www.caratherapeutics.com.

How can I contact Cara Therapeutics?

Cara Therapeutics' mailing address is 107 ELM STREET 9TH FLOOR, STAMFORD CT, 06902. The biopharmaceutical company can be reached via phone at 203-406-3700 or via email at [email protected]

This page was last updated on 12/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.